Overview

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2024-12-25
Target enrollment:
Participant gender:
Summary
Objective 1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment. 2. To evaluate the safety of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.